Nurix Therapeutics to Participate in Upcoming Investor Conference
Nurix Therapeutics, Inc. (Nasdaq: NRIX) announced that its president and chief executive officer, Arthur Sands, M.D., Ph.D., will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026. The company is a clinical-stage biopharmaceutical firm focused on targeted protein degradation medicines for cancer and autoimmune diseases. Nurix has a pipeline of wholly-owned and partnered programs, leveraging its AI-integrated discovery engine and ligase expertise.
Live April 13: Nurix CEO slated for Needham healthcare webcast
Nurix Therapeutics (Nasdaq: NRIX) has announced that its President and CEO, Arthur T. Sands, will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026, from 1:30–2:10 p.m. ET. The session will be webcast live and an archived version will be available on the Investors section of the company's website for 30 days. Nurix is a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines for cancer and autoimmune diseases.
Nurix Therapeutics (NASDAQ:NRIX) Trading 7.3% Higher - Still a Buy?
Nurix Therapeutics (NASDAQ:NRIX) saw its shares trade up 7.3% on Monday, reaching $16.64, although on below-average volume. Despite being unprofitable, the company slightly beat EPS and revenue estimates, and analysts have an average "Moderate Buy" rating with a target price of $30.54. Insider activity in late January showed sales by executives, reducing their positions in the company.
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Consensus Rating of "Moderate Buy" from Analysts
Nurix Therapeutics (NASDAQ:NRIX) has received a consensus "Moderate Buy" rating from fifteen analysts, with an average 12-month price target of $30.54. The company reported EPS of ($0.82), exceeding estimates by $0.02, and revenue of $13.58 million. Insiders recently sold shares, reducing their stakes, while institutional investors like Invesco Ltd. increased their positions.
NRIX Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for Nurix Therapeutics Inc (NRIX). It details the current technical sentiment as "Buy," based on various indicators like RSI, MACD, and moving averages, and outlines key support and resistance levels. The report suggests that NRIX is trading above its 200-day moving average, indicating a long-term bullish trend.
Nurix Therapeutics chief legal officer Ring sells $124k in stock
Christine Ring, Chief Legal Officer of Nurix Therapeutics (NASDAQ:NRIX), sold 8,148 shares of common stock for $124,148 on April 2, 2026, through a pre-arranged trading plan. This sale occurred after NRIX stock surged 71% in the past six months, even though InvestingPro data indicates it remains slightly undervalued. Nurix has also recently amended an equity distribution agreement to sell up to $413.65 million in stock and received increased price targets from analysts following its Q4 fiscal 2025 results and progress in its bexobrutideg program.
Insider Sell: Christine Ring Sells Shares of Nurix Therapeutics Inc (NRIX)
Christine Ring, Chief Legal Officer of Nurix Therapeutics Inc (NRIX), sold 8,148 shares of the company on April 2, 2026. This transaction follows other insider sells for the company, with no insider buys in the past year. The stock is currently trading at $15.24, which is considered significantly overvalued based on its GF Value of $10.40.
Nurix Therapeutics chief legal officer Ring sells $124k in stock
Christine Ring, Nurix Therapeutics' Chief Legal Officer, sold 8,148 shares of NRIX stock worth $124,148, executed under a pre-arranged Rule 10b5-1 trading plan. This sale occurred as NRIX stock surged 71% over the past six months, despite being considered slightly undervalued. The company recently amended its equity distribution agreement to potentially raise up to $413.65 million and has received increased price targets from analysts following its Q4 fiscal 2025 results and promising bexobrutideg program.
Nurix (NRIX) legal chief sells 8,148 shares under 10b5-1 plan
Nurix Therapeutics' Chief Legal Officer, Christine Ring, sold 8,148 shares of NRIX common stock at a weighted average price of $15.2367 per share. This transaction was conducted under a pre-scheduled Rule 10b5-1 trading plan, indicating it was not a discretionary sale based on new information. Following the sale, Ring directly holds 26,453 Nurix shares.
8,148-Share Rule 144 Notice for NRIX (NASDAQ: NRIX)
A Rule 144 notice has been filed for Nurix Therapeutics, Inc. (NASDAQ: NRIX) by Morgan Stanley Smith Barney LLC Executive Financial Services, listing 8,148 shares of common stock tied to Restricted Stock Units for resale. The filing also details multiple 10b5-1 sales by Christine Ring on various dates in early 2026, showing the proceeds from these transactions. This notice provides transparency regarding the potential release of restricted shares into the public market and recent insider trading activity.
Liquidity Mapping Around (NRIX) Price Events
This article provides a liquidity mapping analysis for Nurix Therapeutics Inc. (NRIX), highlighting a neutral near and mid-term outlook with a potentially moderating long-term positive bias. It presents exceptional risk-reward setups and outlines three distinct AI-generated trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, tailored for different risk profiles. The analysis also includes multi-timeframe signal data, indicating support and resistance levels.
Nurix Therapeutics (NRIX) moves 6.9% higher: Will this strength last?
This article discusses Nurix Therapeutics (NRIX) stock, which saw a 6.9% increase. The analysis aims to determine if this upward trend is sustainable.
Vanguard disaggregates holdings; Nurix (NRIX) beneficial ownership shown as 0%
The Vanguard Group has filed an amended Schedule 13G/A for Nurix Therapeutics Inc. (NRIX), stating it now beneficially owns 0% of the company's common stock. This change is due to an internal realignment completed in January 2026, which disaggregates reporting responsibilities to various Vanguard subsidiaries, in reliance on SEC Release No. 34-39538. This administrative change means future institutional holdings by Vanguard-affiliated entities will be reported under separate filings.
Bexobrutideg data and cash position anchor Nurix (NASDAQ: NRIX) 2026 proxy
Nurix Therapeutics has issued its 2026 proxy statement, highlighting significant pipeline progress for its BTK degrader, bexobrutideg, which demonstrated strong objective response rates and progression-free survival in heavily pretreated CLL and Waldenström macroglobulinemia. The company finished fiscal 2025 with $592.9 million in cash and marketable securities and secured a $250 million offering, underscoring a strong financial position to advance its clinical programs. Stockholders will vote on directors, auditor ratification, and executive compensation at a virtual annual meeting on May 15, 2026.
Nurix Therapeutics (NASDAQ:NRIX) Trading Up 10.9% - Time to Buy?
Nurix Therapeutics (NASDAQ:NRIX) saw its stock price jump 10.9% to $16.01 on Wednesday, although trading volume was below average. Wall Street analysts maintain a "Moderate Buy" consensus rating with a target price of $30.54. Despite slightly beating Q4 earnings estimates, the company remains unprofitable and has seen recent insider selling.
Nurix Therapeutics Announces Presentations Showcasing Depth Of Research Pipeline And Scientific Leadership At The American Association For Cancer Research (AACR) Annual Meeting
Nurix Therapeutics announced its plans to present new research at the American Association for Cancer Research (AACR) Annual Meeting. The presentations will highlight the depth of the company's research pipeline and its leadership in scientific innovation. This news was released via Refinitiv and is relevant to investors tracking NRIX stock.
Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting
Nurix Therapeutics will present two oral and three poster presentations at the AACR 2026 Annual Meeting, highlighting their research pipeline and scientific leadership in targeted protein degradation. The presentations will validate CBL-B, AURKA, and mutant BRAF as therapeutic targets in cancer, showcasing Nurix's orally bioavailable degraders in preclinical models. Additionally, Nurix's Chief Scientific Officer, Gwenn Hansen, Ph.D., will speak on induced proximity pharmacology in an AACR Advances session.
Nurix Therapeutics plans oral presentation on multiple degrader programs at San Diego conference
Nurix Therapeutics announced it will deliver an oral presentation at the upcoming AACR26 Annual Meeting in San Diego. The presentation will detail preclinical data from several of its degrader programs, highlighting advancements in its targeted protein degradation pipeline. This initiative aims to broaden therapeutic applications for cancer and various other diseases.
Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting
Nurix Therapeutics will present five scientific presentations, including two oral and three poster presentations, at the AACR 2026 Annual Meeting. These presentations will highlight the company's research pipeline and scientific leadership, focusing on the mechanistic validation of CBL-B, AURKA, and BRAF as therapeutic targets in various cancer indications. Additionally, Nurix's CSO, Gwenn Hansen, will speak on induced proximity pharmacology.
Cancer meeting to feature 5 Nurix studies, including brain tumor data
Nurix Therapeutics will present five studies at the AACR 2026 Annual Meeting, comprising two oral presentations and three poster presentations. These presentations will focus on its research pipeline targeting CBL-B, AURKA, and mutant BRAF, highlighting the potential of its orally bioavailable degraders in preclinical cancer models, including brain tumors. Gwenn Hansen, Nurix's CSO, will also speak on induced proximity pharmacology.
Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research 2026 Annual Meeting
Nurix Therapeutics (Nasdaq: NRIX) will present five research highlights, including two oral and three poster presentations, at the American Association for Cancer Research (AACR) 2026 Annual Meeting. These presentations will detail the mechanistic validation of CBL-B, Aurora kinase A (AURKA), and mutant BRAF as therapeutic targets in various cancer types and showcase Nurix's orally bioavailable degraders. Additionally, Nurix's Chief Scientific Officer, Gwenn Hansen, Ph.D., will speak on induced proximity pharmacology in an AACR Advances session.
Why (NRIX) Price Action Is Critical for Tactical Trading
This article analyzes Nurix Therapeutics Inc. (NASDAQ: NRIX) stock, highlighting a critical mid-channel oscillation pattern and a significant 78.3:1 risk-reward setup targeting a 22.7% gain. It details three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, despite weak near and mid-term sentiment, with a strong long-term outlook.
Stocks to watch: Nurix Therapeutics sees relative strength rating jump to 83
The article highlights that Nurix Therapeutics (NRIX) has seen its IBD Relative Strength Rating jump to 83, indicating strong stock performance compared to other companies. This rating improvement suggests increased investor interest and positive momentum for the company's shares.
Cinctive Capital Management LP Raises Stock Holdings in Nurix Therapeutics, Inc. $NRIX
Cinctive Capital Management LP significantly increased its stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 64.5% during the third quarter, now owning 191,015 shares valued at $1.765 million. Several other institutional investors also adjusted their positions in the company. Analysts hold a "Moderate Buy" consensus rating for Nurix Therapeutics, with an average price target of $30.54, despite recent insider stock sales from the CFO and another insider.
Nurix Therapeutics, Inc. $NRIX Stake Cut by Commodore Capital LP
Commodore Capital LP reduced its stake in Nurix Therapeutics (NRIX) by 4.3% in the third quarter of 2025, selling 168,598 shares and now holding 3,780,055 shares valued at approximately $34.9 million. Despite this, analysts maintain a "Moderate Buy" rating with an average price target of $29.50, and the company reported better-than-expected Q3 earnings. However, the company faces negative net margins and recent insider share sales.
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Average Rating of "Moderate Buy" from Analysts
Nurix Therapeutics, Inc. (NASDAQ:NRIX) has received a consensus "Moderate Buy" rating from 16 analysts, with an average 12-month target price of $29.50. Recent analyst reports show increased bullishness, with price targets raised by several firms and the highest new target set at $36. Despite trading around $15.95 and having a $1.64 billion market cap, the company remains unprofitable, and insiders have recently sold shares.
A Look At Nurix Therapeutics (NRIX) Valuation After Expanded Equity Distribution Agreement
Nurix Therapeutics (NRIX) recently expanded its equity distribution agreement to sell up to $413.65 million in common stock, impacting its capital-raising flexibility and potential dilution. The company's stock has declined over the past quarter but shows stronger long-term returns. Despite projected 37.9% annual revenue growth, Nurix is expected to remain unprofitable for the next three years, and its current Price-to-Sales (P/S) ratio of 19x is considered overvalued compared to industry and peer averages, suggesting significant downside risk.
A Look At Nurix Therapeutics (NRIX) Valuation After Expanded Equity Distribution Agreement
Nurix Therapeutics recently expanded its equity distribution agreement to sell up to $413.65 million of common stock, impacting its capital-raising flexibility and potential dilution. Despite recent share price declines, long-term returns remain positive. The company's current Price-to-Sales ratio of 19x is considered overvalued compared to biotech peers and fair value estimates, indicating investors are paying for future revenue growth despite expected unprofitability over the next three years.
Understanding Momentum Shifts in (NRIX)
This article analyzes Nurix Therapeutics Inc. (NASDAQ: NRIX), highlighting weak near-term sentiment despite long-term strength. It details an exceptional 66.0:1 risk-reward short setup and provides institutional trading strategies for different risk profiles, including position trading, momentum breakout, and risk hedging strategy. The analysis also includes multi-timeframe signal analysis with support and resistance levels.
Does Nurix Therapeutics' (NRIX) Expanded ATM Capacity Reframe Its Balance Between Funding Flexibility and Dilution?
Nurix Therapeutics has expanded its at-the-market (ATM) facility, allowing it to sell up to US$413.65 million in common stock. This provides increased funding flexibility for its pipeline and partnerships but also raises concerns about potential shareholder dilution, especially given its history of losses and a recent US$250 million offering. Investors face a trade-off between the company's funding runway and the risk of further dilution, as profitability is not expected soon.
Rhenman & Partners Asset Management AB Purchases 162,500 Shares of Nurix Therapeutics, Inc. $NRIX
Rhenman & Partners Asset Management AB increased its stake in Nurix Therapeutics by 87.8%, purchasing 162,500 additional shares to hold a total of 347,500 shares valued at $3.21 million. Analysts maintain a "Moderate Buy" rating with an average price target of $29.50, and the company recently reported better-than-expected Q4 earnings and revenue. Despite insider share sales, other institutional investors have also modified their holdings, reflecting varied sentiment.
Nurix Therapeutics amends equity distribution agreement for $413.65 million stock offering
Nurix Therapeutics has amended its equity distribution agreement with Piper Sandler & Co. to allow for the offering and sale of up to $413.65 million in common stock through "at the market" offerings. This move follows recent positive analyst updates, with firms like H.C. Wainwright, Stifel, Piper Sandler, RBC Capital, and BTIG raising price targets and reiterating "Buy" or "Outperform" ratings based on Nurix's financial results and progress in its bexobrutideg program. The company's strategic initiatives and strong cash position have contributed to analysts' confidence.
Nurix Therapeutics amends equity distribution agreement for $413.65 million stock offering
Nurix Therapeutics (NASDAQ:NRIX) has amended its equity distribution agreement with Piper Sandler & Co. to offer and sell up to $413.65 million of common stock through "at the market" offerings, including previously sold shares. This move follows positive analyst updates, with several firms raising price targets due to the potential of Nurix's bexobrutideg program and strong financial positioning. The company recently reported a net loss of $0.82 per share for Q4 fiscal 2025, which was better than analyst estimates.
Nurix Therapeutics adds $413.65M at-the-market equity facility with Piper Sandler
Nurix Therapeutics has amended its equity distribution agreement with Piper Sandler, expanding its at-the-market program to sell up to $413.65 million of common stock. This amount includes shares already sold, and the offerings will be made via the company's Form S-3 automatic shelf registration. The details are available in the filed Amendment No. 3 and a legal opinion.
Nurix Therapeutics Expands ATM Equity Offering Capacity
Nurix Therapeutics (NRIX) has expanded its at-the-market (ATM) equity program with Piper Sandler, allowing it to sell up to $413.65 million in common stock. This move is intended to support the company's financial flexibility and growth plans, despite an AI analyst ranking the stock as "Neutral" due to heavy losses and cash burn. The expansion leverages existing SEC registrations, including shares already sold.
Nurix Therapeutics (NASDAQ: NRIX) updates $413.65M ATM stock capacity
Nurix Therapeutics, Inc. (NASDAQ: NRIX) has updated its "at the market" (ATM) stock offering program, allowing the company to offer and sell up to $413.65 million of its common stock through Piper Sandler. This update was enacted through Amendment No. 3 to its equity distribution agreement. The offering is executed under its existing automatic shelf registration statement, enabling Nurix to opportunistically raise capital.
ARK Investment Management LLC Has $13.96 Million Position in Nurix Therapeutics, Inc. $NRIX
ARK Investment Management LLC reduced its stake in Nurix Therapeutics by 4.1% in Q3, now holding 1,510,404 shares valued at approximately $13.96 million. Other institutional investors like Millennium Management LLC and Goldman Sachs Group Inc. increased their positions, while company insiders Gwenn Hansen and CFO Houte Hans Van sold shares in January. Nurix Therapeutics slightly beat quarterly EPS estimates, has a market cap of $1.67 billion, and an average analyst rating of "Moderate Buy" with a consensus price target of $29.50.
Nurix Therapeutics, Inc. $NRIX Stock Position Increased by Amova Asset Management Americas Inc.
Amova Asset Management Americas Inc. has increased its stake in Nurix Therapeutics (NASDAQ:NRIX) by 12.1% in the third quarter, bringing its total ownership to 1,557,479 shares valued at approximately $14.39 million. Other institutional investors like Sumitomo Mitsui Trust Group Inc. and Geode Capital Management LLC also adjusted their positions. Nurix Therapeutics, a clinical-stage biopharmaceutical company, has received a "Moderate Buy" consensus rating from analysts with an average price target of $29.50, despite reporting a negative EPS for Q4 and ongoing unprofitability.
NRIX SEC Filings - Nurix Therapeutics, Inc. 10-K, 10-Q, 8-K Forms
This page provides comprehensive access to Nurix Therapeutics, Inc. (NRIX) SEC filings, including annual 10-K reports, quarterly 10-Q earnings, and 8-K material event forms. It details recent filings covering underwriting agreements for stock offerings, clinical trial updates for bexobrutideg and NX-1607, and changes to the board of directors. The platform also offers AI-powered summaries of these documents and real-time updates for investors tracking the biopharmaceutical company's regulatory disclosures.
Handelsbanken Fonder AB Buys 240,000 Shares of Nurix Therapeutics, Inc. $NRIX
Handelsbanken Fonder AB significantly increased its stake in Nurix Therapeutics, Inc. by 85.7%, purchasing 240,000 additional shares to bring its total holding to 520,000 shares, valued at $4.805 million. This move comes as several brokerages have raised price targets for Nurix, with the company also reporting a slight beat on its quarterly EPS estimates. Despite the institutional buying interest, company insiders have recently sold shares.
Insider Sell: Christine Ring Sells Shares of Nurix Therapeutics Inc (NRIX)
Christine Ring, Chief Legal Officer of Nurix Therapeutics Inc (NRIX), sold 8,148 shares of the company on March 2, 2026, bringing her total ownership to 34,601 shares. The company has seen 21 insider sells and no buys over the past year. At the time of sale, Nurix Therapeutics was trading at $15.44 per share, indicating it is significantly overvalued based on its GuruFocus Value of $10.72.
Planned stock sale by Nurix (NRIX) chief legal officer disclosed
Nurix Therapeutics, Inc.'s Chief Legal Officer, Christine Ring, sold 8,148 shares of common stock at a weighted average price of $15.4385 per share on March 2, 2026. This transaction was executed under a pre-arranged 10b5-1 trading plan. Following the sale, Ring directly holds 34,601 shares of Nurix common stock.
Christine Ring sells RSU shares (NRIX) under 10b5-1 plan via Morgan Stanley
Christine Ring, an insider at Nurix Therapeutics (NRIX), has filed a Form 144 to sell 8,148 common shares from Restricted Stock Units through Morgan Stanley. The filing indicates previous 10b5-1 sales by Ms. Ring on December 18, 2025, January 20, 2026, and February 9, 2026. This transaction is characterized as a routine compliance disclosure for planned sales under a 10b5-1 trading plan.
NRIX Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a detailed financial overview of Nurix Therapeutics, Inc. (NRIX), including its income statement, balance sheet, cash flow statement, and key financial ratios. It highlights that NRIX's revenue surged by 54.0% in fiscal year 2025, but the company remains unprofitable with a net income of -$264.5M and a low Piotroski F-Score of 3/9, indicating weak financial health. Despite strong liquidity and low leverage, its profitability and cash flow scores are low due to significant operating losses and high capital investment.
Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million
Redmile Group increased its stake in Nurix Therapeutics (NASDAQ:NRIX) by $63.43 million, despite the stock being down 6% over the past year. This significant investment makes Nurix Therapeutics the third-largest holding in Redmile Group’s portfolio, representing 11.31% of its AUM. The move comes as Nurix advances its lead BTK degrader into a registrational program, hinting at potential future growth despite current stock volatility and substantial R&D spending.
Baker Bros discloses 7.2% Nurix (NRIX) ownership stake
Baker Bros. has filed an amended Schedule 13G, disclosing a 7.2% ownership stake in Nurix Therapeutics, Inc. (NRIX). This ownership amounts to 7,527,996 shares, which includes common stock and shares issuable from pre-funded warrants. The investment group, led by Baker Bros. Advisors LP, is reporting its position on a passive basis.
Discipline and Rules-Based Execution in NRIX Response
This article provides an analysis of Nurix Therapeutics Inc. (NASDAQ: NRIX), highlighting weak near and mid-term sentiment that could challenge a positive long-term outlook. Key findings include resistance being tested, and an exceptional risk-reward short setup. The article details institutional trading strategies with entry points, targets, and stop losses for position trading, momentum breakout, and risk hedging.
Nurix Therapeutics Highlights STAT6, BTK and IRAK4 Degraders as Immunology Pipeline Gains Spotlight
Nurix Therapeutics is emphasizing its immunology and inflammation pipeline, which leverages targeted protein degraders for STAT6, BTK, and IRAK4. The company argues that degraders offer advantages over traditional inhibitors by removing the entire protein, addressing non-enzymatic scaffolding functions, and enabling targeting of difficult-to-drug proteins like STAT6. Key programs include the STAT6 degrader NX-3911 (partnered with Sanofi), a BTK degrader (bexobrutideg) in a tablet formulation for autoimmune uses, and an IRAK4 degrader partnered with Gilead, with significant updates anticipated for 2026.
Nurix Therapeutics, Inc. (NRIX) Stock Analysis: Emerging Potential With 90% Upside
Nurix Therapeutics (NRIX) is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and inflammatory conditions. Despite being unprofitable with a negative P/E ratio and EPS, analysts are highly optimistic, setting an average target price of $30.00, representing a 90.72% potential upside. The company's promising drug pipeline and strategic partnerships with industry giants like Gilead Sciences and Pfizer support this positive outlook, though investors should be aware of the inherent risks and volatility in the biotech sector.
Assessing Nurix Therapeutics (NRIX) Valuation After Revenue Growth Wider Loss And New Shelf Registration
Nurix Therapeutics (NRIX) reported full-year 2025 earnings with increased revenue but a wider net loss, alongside a new shelf registration. The company's stock has seen recent volatility, and its Price-to-Sales ratio of 20.6x is considered overvalued compared to industry averages and an estimated fair value. This valuation suggests that significant execution will be required to support the current share price, especially given the company's unprofitability and reliance on early-stage trials.
